Dimerix (ASX: DXB) Discussion Thread, page-3

Can't imagine the market not being confident. The recent licensing deal is a pretty clear sign that those who are far more knowledgeable than most ASX investors see great potential here. Usually the US is the most lucrative market for new drugs, so the fact they've scored this quite impressive deal which doesn't even include the US is a strong signal of the potential here. Once we have the data, I can't see how we don't score a US deal many multiples larger than the recent one

My view is simply the market is not recognising what we have yet. This is not exactly uncommon, especially for lower MC stocks there just isn't a lot of research. Not sure what will cause this to change, perhaps FOMO will arrive closer to the readout or the announcement itself will trigger the buying... who knows